Kisspeptin-10

Kisspeptin-10 is a short peptide fragment of the larger kisspeptin protein, known to scientists as metastin 45-54. It acts as a key that fits into a specific lock, the kisspeptin receptor (KISS1R), found on brain cells that control reproductive hormone release. Because it sits upstream of gonadotropin-releasing hormone (GnRH), it can trigger the pituitary gland to release luteinizing hormone (LH) and, to a lesser extent, follicle-stimulating hormone (FSH). Researchers study it mainly as a tool to test how well the hypothalamus is working, and as a way to induce ovulation or boost testosterone in certain conditions Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders. Unlike longer kisspeptin versions, it clears from the body very quickly, which limits its use outside of carefully timed infusions Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10.

Kisspeptin-10 binds to and activates the kisspeptin receptor KISS1R/GPR54, a G protein-coupled receptor found on GnRH-producing neurons in the brain Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function. This activation causes a rapid influx of calcium and triggers signaling pathways that lead to GnRH release, which then prompts the pituitary to secrete LH and FSH Dynamic Kisspeptin Receptor Trafficking Modulates Kisspeptin-Mediated Calcium Signaling Functional examination of novel kisspeptin phosphinic peptides. In men, a 24-hour IV infusion at 12.5 mcg/kg/h raised LH levels roughly 5- to 8-fold above baseline, with smaller rises in FSH and testosterone Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. However, the effect is pattern-dependent: continuous exposure leads to a partial decline after the initial spike, likely due to receptor desensitization and internalization Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men Dynamic Kisspeptin Receptor Trafficking Modulates Kisspeptin-Mediated Calcium Signaling. This makes pulsatile or intermittent dosing more rational for sustained stimulation, while continuous exposure is used experimentally to study the axis' response to constant drive Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men Continuous human metastin 45-54 infusion desensitizes G protein-coupled receptor 54-induced gonadotropin-releasing hormone release monitored indirectly in the juvenile male Rhesus monkey (Macaca mulatta): a finding with therapeutic implications.

Beyond reproduction, kisspeptin-10 also influences metabolism: it can affect insulin and glucose handling in primates, and genetic loss of kisspeptin in mice leads to obesity and altered energy expenditure The role of Kiss1 neurons in regulating metabolism and energy balance Study on the Effect of Peripheral Kisspeptin Administration on Basal and Glucose-induced Insulin Secretion Under Fed and Fasting Conditions in the Adult Male Rhesus Monkey (<i>Macaca mulatta)</i>. In tissues outside the brain, kisspeptin-10 can modulate bone cells, blood vessel function, and even heart fibroblast activity, showing that its receptor is present in many body systems Kisspeptin-10 attenuates pulmonary arterial hypertension via restoration of mitochondrial function in pulmonary artery smooth muscle cells Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures.

Hormonal stimulation

The clearest effect in human studies is a marked increase in LH. In healthy men, continuous IV infusion raised LH from about 3 mIU/mL to 17–31 mIU/mL, peaking around 12–20 hours Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Testosterone rises more modestly, reaching high-normal levels Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. In women, kisspeptin-10 infusion increases LH, FSH, and estradiol, and can reactivate the dormant hypothalamic-pituitary-ovarian axis in hyperprolactinemic amenorrhea Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea.

Ovulation and fertility

In a subset of women with polycystic ovary syndrome (PCOS), repeated kisspeptin-54 treatment induced gonadotropin responses and ovulation, though only about half of patients responded, and one showed desensitization Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome. Robust human data for kisspeptin-10 in PCOS ovulation induction are lacking. Animal studies confirm that kisspeptin can rescue ovulation in some PCOS models but not others, depending on the underlying hormonal defect Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome Prolonged oscillating preoptic area kisspeptin neuron activity underlies the preovulatory luteinizing hormone surge in mice. In livestock, kisspeptin-10 improved estrus synchronization and ovulation timing Effects of kisspeptin-10 on the reproductive performance of sows in a fixed-time artificial insemination programme Study of Estrus Synchronization Protocols in Sahiwal Heifers Using Kisspeptin (Kp-10) and Gonadotropin Releasing Hormone (GnRH).

Anti‑cancer and tissue effects

Preclinical work points to kisspeptin-10’s ability to suppress metastasis and tumor growth in some cancers by downregulating VEGF and other pathways Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10 Exogenous kisspeptin-10 treatment shows pleiotropy via induction of KISS1 expression, metastasis suppression, and promotes apoptosis in triple-negative breast cancer Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory axis. It also reduced bone loss in osteoporotic models by inhibiting osteoclast activity Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src, and attenuated pulmonary hypertension in animal models Kisspeptin-10 attenuates pulmonary arterial hypertension via restoration of mitochondrial function in pulmonary artery smooth muscle cells. These effects, while promising, lack human trial validation.

Evidence gaps

Most effects beyond acute LH stimulation are derived from animal or cell studies. The anti‑cancer, metabolic, and vascular effects are not yet proven in humans, and the fertility‑enhancing potential is inconsistent across studies Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome Kisspeptin exacerbates androgen-induced follicular dysplasia by promoting Drp1 phosphorylation imbalance and mitochondrial excessive fission in granulosa cells of polycystic ovary syndrome.

Most published human protocols use intravenous infusion. One common method is a continuous IV drip at 12.5 mcg/kg/h for 24 hours, which reliably spikes LH and FSH Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. For diagnostic testing, a single IV bolus of 1 mcg/kg has been used in animals, but no human data support this approach; human diagnostic use remains experimental Provocative tests with Kisspeptin-10 and GnRH set the scene for determining social status and environmental impacts on reproductive capacity in male African lions (Panthera leo). In women, a lower infusion rate of 1.5 μg/kg/h over 12 hours successfully restarted the menstrual axis in hyperprolactinemia Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea.

Subcutaneous use, while popular in research settings outside of hospitals, is not well‑documented in controlled trials. Community protocols often involve 100‑500 mcg per injection, once or twice daily, timed around fertility windows or for general endocrine support. However, the rapid clearance of kisspeptin‑10 (half‑life ~4 minutes in mice) means that SC pulses are short‑lived, and frequent administration may be needed to sustain any effect Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. To avoid receptor desensitization, most regimens incorporate rest periods every few weeks Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.

For men, a typical SC research dose might be 200‑400 mcg once daily, often in the morning to match natural hormone rhythms. For women aiming to trigger ovulation, protocols align with the follicular phase, with injections timed based on ultrasound monitoring. No oral or nasal forms have been studied; injectable routes are the only ones with evidence.

Lyophilized kisspeptin‑10 is typically reconstituted with bacteriostatic water for multi‑dose use. Because the peptide degrades quickly, small aliquot volumes and cold storage are recommended Prolonged oscillating preoptic area kisspeptin neuron activity underlies the preovulatory luteinizing hormone surge in mice LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats. After adding the diluent, swirl gently and let it dissolve for several minutes; do not shake. The resulting solution should be clear and free of particles.

Store unmixed powder at −20°C for long‑term storage, or at 2–8°C for short‑term. Once reconstituted, keep the vial refrigerated and protect from light. Use within 2–4 weeks, and avoid repeated warming cycles. For longer storage, freeze individual syringes or small aliquots at −20°C, and thaw only once before use Safety Evaluation of KP-10 (Metastin 45–54) following once daily intravenous administration for 14 days in Dog. The interactive calculator on this page can help you determine how much diluent to add and what volume to draw for your target dose.

Hormonal medications

Combining kisspeptin‑10 with other fertility drugs (hCG, clomiphene, gonadotropins) can cause excessive ovarian or testicular stimulation Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome. Estrogen‑based therapies, including birth control, may alter the response: estrogen priming can enhance the LH surge, while anti‑estrogens may blunt it Estradiol Priming Potentiates the Kisspeptin-Induced Release of LH in Ovariectomized Cows. Prolactin‑elevating drugs like antipsychotics could interact, since kisspeptin can raise prolactin indirectly Kisspeptin Stimulation of Prolactin Secretion Requires Kiss1 Receptor but Not in Tuberoinfundibular Dopaminergic Neurons.

Metabolic and inflammatory states

In states of energy deficit (severe dieting, overtraining), kisspeptin’s effect is often dampened because the brain’s kisspeptin neurons integrate metabolic signals Food restriction during lactation suppresses <i>Kiss1</i> mRNA expression and kisspeptin-stimulated LH release in rats. Similarly, systemic inflammation from illness or injury can suppress LH pulses and reduce responsiveness Central fractalkine-CX3CR1 signaling mediates systemic LPS-induced inhibition of LH pulses in female rats. Drugs that lower blood glucose (insulin, sulfonylureas) may have an unpredictable interaction, as kisspeptin influences glucose homeostasis Study on the Effect of Peripheral Kisspeptin Administration on Basal and Glucose-induced Insulin Secretion Under Fed and Fasting Conditions in the Adult Male Rhesus Monkey (<i>Macaca mulatta)</i> Peripherally administered KP-10 prevents development of insulin-induced hypoglycemic shock in diabetic rhesus monkeys.

Other peptides

Using kisspeptin‑10 alongside other kisspeptin analogs or GnRH agonists is redundant and risks overstimulation. Stacking with growth hormone secretagogues is theoretically possible and often done, but no studies confirm any synergy Bioengineered recombinant kisspeptins with extended half-life exhibit novel peripheral function in a large-animal model.

Kisspeptin‑10 is sometimes combined with other peptides that support fertility or metabolism, but formal studies are lacking. In theory, pairing it with a gonadotropin like hCG could amplify its LH‑like signal, but this increases the risk of overstimulation and is not recommended outside specialist protocols Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men Bioengineered recombinant kisspeptins with extended half-life exhibit novel peripheral function in a large-animal model. Stacking with growth hormone‑releasing peptides (GHRPs) or GHRH analogs is popular among researchers aiming to boost both growth hormone and testosterone, though there is no direct evidence of benefit Bioengineered recombinant kisspeptins with extended half-life exhibit novel peripheral function in a large-animal model. Some protocols pair kisspeptin‑10 with kisspeptin‑54 for a sustained effect, but the different kinetics may lead to unpredictable hormone fluctuations.

Overall, kisspeptin‑10’s main role is as a short‑acting hypothalamic activator, so it is usually used alone for targeted diagnostic or fertility purposes. Adding multiple hormones to the stack often complicates interpretation rather than yielding clear benefits Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.

Kisspeptin‑10 is not approved by the FDA or any major regulatory agency as a marketed drug. All human data comes from clinical physiology studies, not phase III trials Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders. In sports, its ability to raise LH and testosterone makes it a concern for anti‑doping authorities; analytical methods have been developed to detect it in urine and blood for doping control Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography–High‐Resolution Mass Spectrometry for Doping Control Purposes Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry. Kisspeptin-10 was added to the WADA Prohibited List in 2024, explicitly banning its use as a peptide hormone and hormone modulator Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography–High‐Resolution Mass Spectrometry for Doping Control Purposes.

In the United States and many other countries, possession is legal for research use only, but selling it for human consumption could violate regulations. No specific scheduling information is available in the source documents, so it is treated as an investigational compound.

Hormonal side effects

The most common effects are directly from the hormonal surge: flushing, headache, nausea, and transient increases in libido. In men, testosterone may rise temporarily, which could cause acne or mood swings in sensitive individuals Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Excessive or continuous dosing can lead to receptor desensitization, where the axis partially attenuates—LH may decline from its peak but often remains elevated after prolonged infusion Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men Continuous human metastin 45-54 infusion desensitizes G protein-coupled receptor 54-induced gonadotropin-releasing hormone release monitored indirectly in the juvenile male Rhesus monkey (Macaca mulatta): a finding with therapeutic implications.

Reproductive and developmental risks

Animal studies raise several red flags. In prepubertal male rats, repeated high‑dose kisspeptin‑10 caused Leydig cell damage and reduced testosterone Dose-Dependent Degeneration of Leydig Cells Following Kisspeptin-10 Administration: An Ultrastructural Study. In women, kisspeptin may affect placental invasion during pregnancy, so it should be avoided in anyone who is or might become pregnant Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. Prolactin elevation has been observed in some models, which could disrupt menstrual cycles or cause breast tenderness Kisspeptin Stimulation of Prolactin Secretion Requires Kiss1 Receptor but Not in Tuberoinfundibular Dopaminergic Neurons.

Contraindications

Kisspeptin‑10 is contraindicated during pregnancy, in hormone‑sensitive cancers, and in children unless under strict medical supervision. It should be used cautiously in anyone with high baseline LH (such as some PCOS subtypes) or eating disorders, because the endocrine environment may blunt or distort the response Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome Food restriction during lactation suppresses <i>Kiss1</i> mRNA expression and kisspeptin-stimulated LH release in rats. Long‑term human safety data are absent; all extended‑use protocols should include regular hormone monitoring.